{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-254615","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-06-03T11:58:30+00:00","discovered_at":"2026-06-03T12:00:01.308908+00:00","generated_at":"2026-06-03T12:00:20.663574+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NewAmsterdam Pharma shareholders approve 2026 ESPP, re-elect directors at AGM","bullets":["Shareholders approved 2026 Employee Stock Purchase Plan; up to 1,150,000 ordinary shares available, 15% discount on lower of start/end market price.","Purchase periods generally 6 months; payroll deductions 1%-15% of compensation; plan expires June 2, 2036.","Re-appointed John W. Smither and Janneke van der Kamp as non-executive directors until 2030 AGM.","Board authorized to issue shares (including without pre-emption rights) through June 2, 2031.","Say-on-pay passed with 81.1M for; Deloitte ratified as auditor for FY2026; quorum 78.3%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-254615","json":"https://secwatch.observer/filing/0001193125-26-254615.json","markdown":"https://secwatch.observer/filing/0001193125-26-254615.md","text":"https://secwatch.observer/filing/0001193125-26-254615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/nams-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:00:20.663574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13142b9b242717270d8feab1754bb44db9d2fe16","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Ratification of Deloitte Accountants B.V. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 4. The Company’s shareholders ratified the selection by the Company’s Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,502,639 4,618 31,355 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"3e375fc0dcb49289ae0de6bb81b5cf09010717fb","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Extension of authorization for Board to limit or exclude pre-emption rights for five-year period ending June 2, 2031 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 7. The Company’s shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031. The votes cast were as follows: For Against Abstain Broker Non-Votes 57,890,766 28,450,917 45,319 5,151,610","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"6257235e1892b6a97b4aedd1386871f71f6e133f","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Non-binding advisory vote on 2025 compensation of named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 9. The Company’s shareholders approved the 2025 compensation of the Company’s named executive officers by a non-binding, advisory (“Say-on-Pay”) vote. The votes cast were as follows: For Against Abstain Broker Non-Votes 81,100,259 4,946,963 339,780 5,151,610","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"6d421dc9418a8eacf6601edefeed30fa86926d9e","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Re-appointment of two non-executive directors at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 5. The Company’s shareholders approved the re-appointment of each of the two nominees listed below as a non-executive director of the Company, each to serve until the annual general meeting of shareholders in 2030, or until their earlier death, resignation or removal. The votes cast were as follows: Name For Against Abstain Broker Non-Votes John W. Smither 85,375,639 956,620 54,743 5,151,610 Janneke van der Kamp 75,256,863 9,899,189 1,230,950 5,151,610","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"7a4a5ea7adef9a6b323b6d1e280f807543084716","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Adoption of Dutch statutory annual accounts for fiscal year ended December 31, 2025 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 1. The Company’s shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,484,326 3,855 50,431 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"8d678569e83f0a2615d1a0f974a348e05dc63a1a","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Approval of ESPP at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 8. The Company’s shareholders approved the ESPP. The votes cast were as follows: For Against Abstain Broker Non-Votes 86,221,442 139,927 25,633 5,151,610","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"c2244944f25cb4d816529e1324a609049388fd2e","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Discharge from liability for the Company’s directors for fiscal year ended December 31, 2025 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 2. The Company’s shareholders approved the discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2025. The votes cast were as follows: For Against Abstain Broker Non-Votes 85,229,605 1,105,840 51,557 5,151,610","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"cc7a5280a4779b6a0da73acf9b05a5143d76a5a2","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Instruction to Deloitte Accounts B.V. as external auditor for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 3. The Company’s shareholders approved the instruction to Deloitte Accounts B.V. as the external auditor of the Company’s Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,502,529 4,636 31,447 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"f6ebf51abec779b4402c563cd8ad094f75da198e","claim":"NewAmsterdam Pharma Co N.V. shareholders approved Extension of authorization for Board to issue Ordinary Shares for five-year period ending June 2, 2031 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 6. The Company’s shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company’s capital, for a five-year period ending June 2, 2031. The votes cast were as follows: For Against Abstain Broker Non-Votes 59,539,558 26,801,646 45,798 5,151,610","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}